{"type":"trials","record":{"id":41796,"source_id":"clinicaltrials-gov","external_id":"NCT00696592","title":"Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration","brief_summary":"This phase II study was designed to evaluate the safety, tolerability, and efficacy of bevacizumab treatment in conjunction with PDT at the low fluence rate compared with bevacizumab alone or combined with PDT at the standard fluence rate, in patients with all types of choroidal neovascularization secondary to AMD. Hypothesis: bevacizumab in combination with PDT (low and standard fluence rate) will i) delay time to retreatment, ii) reduce the average number of treatments required compared to bevacizumab alone and iii) at low PDT fluence rate will improve long-term safety profile.","overall_status":"Withdrawn","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"University of Padova","enrollment":0,"countries":["Italy"],"start_date":"2007-01-31","completion_date":"2008-01-31","last_update_date":"2025-04-24","source_url":"https://clinicaltrials.gov/study/NCT00696592","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"ARMAST","age_range":"55 Years to 80 Years","comparator":"BVZ only","organization":"University of Padova","interventions":["Bevacizumab (Avastin), Verteporfin (Visudyne)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Bevacizumab injections — One year","The mean change in best-corrected ETDRS visual acuity in the study eye — Months 6 and 12","Mean change in total CNV area (Disc Areas) — Months 6 and 12","Changes of central retinal thickness measured by Optical Coherence Tomography (OCT). — Months 6 and 12","NEI VFQ-25 (vision-related quality of life) score — One year","Pelli-Robson Contrast Sensitivity Score — One year"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Bevacizumab (Avastin), Verteporfin (Visudyne)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct00696592","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2007-01-31 to 2008-01-31","comparator":"BVZ only","confidence":"structured-source","population":"ALL · 55 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.872Z","intervention":["Bevacizumab (Avastin), Verteporfin (Visudyne)"],"participants":0,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Bevacizumab injections — One year","The mean change in best-corrected ETDRS visual acuity in the study eye — Months 6 and 12","Mean change in total CNV area (Disc Areas) — Months 6 and 12","Changes of central retinal thickness measured by Optical Coherence Tomography (OCT). — Months 6 and 12","NEI VFQ-25 (vision-related quality of life) score — One year","Pelli-Robson Contrast Sensitivity Score — One year"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41796","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}